TP53 and hepatocellular carcinoma: Sorafenib resistant HCC cells exhibit the characteristics of activated the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway42, which ultimately limits the induction of apoptosis by the suppression of p53.